Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical efficacy and safety of J022X ST in the prevention of recurrent upper-respiratory tract infections in children
2013-001760-31Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- May 2013
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of polyvalent mechanical bacterial lysate in recurrent upper respiratory tract infection (R-URTI) and upper respiratory infection (URI), sponsored by Pierre Fabre Laboratories. Primary endpoint: Number of URTI episodes medically assessed over year 2. Started May 2013; status: completed.
02
Drugs
polyvalent mechanical bacterial lysate
03
Conditions
recurrent upper respiratory tract infection (R-URTI)upper respiratory infection (URI)
Beyond the preview
Go deeper on 2013-001760-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001760-31.